Insys Therapeutics Inc (INSY) CEO Acquires $53,910.00 in Stock

Insys Therapeutics Inc (NASDAQ:INSY) CEO Saeed Motahari purchased 4,500 shares of the company’s stock in a transaction dated Tuesday, May 16th. The stock was acquired at an average price of $11.98 per share, with a total value of $53,910.00. Following the completion of the transaction, the chief executive officer now owns 4,500 shares of the company’s stock, valued at approximately $53,910. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Insys Therapeutics Inc (NASDAQ:INSY) traded up 3.20% on Friday, reaching $12.59. 808,026 shares of the company’s stock traded hands. The firm’s market cap is $908.05 million. The company’s 50-day moving average price is $10.98 and its 200 day moving average price is $10.88. Insys Therapeutics Inc has a one year low of $8.70 and a one year high of $19.96.

Insys Therapeutics (NASDAQ:INSY) last posted its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.01. Insys Therapeutics had a net margin of 8.71% and a return on equity of 9.39%. The business had revenue of $35.92 million for the quarter, compared to analysts’ expectations of $37.78 million. During the same period in the prior year, the company posted $0.11 EPS. The business’s revenue for the quarter was down 40.5% compared to the same quarter last year. On average, equities analysts forecast that Insys Therapeutics Inc will post ($0.48) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Insys Therapeutics (NASDAQ:INSY)

COPYRIGHT VIOLATION WARNING: This article was posted by Mideast Time and is owned by of Mideast Time. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.mideasttime.com/insys-therapeutics-inc-insy-ceo-acquires-53910-00-in-stock/1708006.html.

A number of hedge funds have recently bought and sold shares of the company. American International Group Inc. boosted its stake in Insys Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,462 shares of the specialty pharmaceutical company’s stock valued at $152,000 after buying an additional 953 shares in the last quarter. Credit Suisse AG boosted its stake in Insys Therapeutics by 8.2% in the first quarter. Credit Suisse AG now owns 31,003 shares of the specialty pharmaceutical company’s stock valued at $326,000 after buying an additional 2,362 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Insys Therapeutics by 5.7% in the first quarter. Schwab Charles Investment Management Inc. now owns 79,468 shares of the specialty pharmaceutical company’s stock valued at $836,000 after buying an additional 4,275 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Insys Therapeutics by 30.3% in the first quarter. Wells Fargo & Company MN now owns 27,541 shares of the specialty pharmaceutical company’s stock valued at $289,000 after buying an additional 6,407 shares in the last quarter. Finally, Parametric Portfolio Associates LLC boosted its stake in Insys Therapeutics by 34.5% in the first quarter. Parametric Portfolio Associates LLC now owns 25,712 shares of the specialty pharmaceutical company’s stock valued at $270,000 after buying an additional 6,600 shares in the last quarter. Institutional investors and hedge funds own 45.21% of the company’s stock.

A number of equities research analysts have recently weighed in on the stock. Jefferies Group LLC dropped their price target on shares of Insys Therapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, April 4th. Piper Jaffray Companies downgraded shares of Insys Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $20.00 to $10.00 in a research report on Wednesday, May 10th. Zacks Investment Research upgraded shares of Insys Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 28th. Oppenheimer Holdings Inc. reiterated a “hold” rating on shares of Insys Therapeutics in a research report on Thursday, April 6th. Finally, Royal Bank of Canada reiterated a “buy” rating and issued a $16.00 price target on shares of Insys Therapeutics in a research report on Friday, April 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $13.50.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

5 Day Chart for NASDAQ:INSY

Receive News & Ratings for Insys Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.